Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 131 participants.
Also called NCT02396758
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 131 participants
- Sponsor
- Registry
-
NCT02396758 -
2016-000502-11
-
- Other papers using this trial's data
- A Randomized Trial of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Intermediate-Risk Pulmonary Embolism: The OPTALYSE PE Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02396758. Randomized; no masking; primary purpose treatment. Start 2015-06-12 (actual); primary completion 2019-04-30 (actual). Results posted on 2021-03-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism
- Acronym
- OPTALYSE PE
- Condition
- Pulmonary Embolism and Thrombosis
- Intervention (Device)
- Ekosonic® Endovascular Device ultrasonic infusion catheter
- Intervention (Biological)
- Recombinant tissue plasminogen activator
- Lead sponsor
- Boston Scientific Corporation
- Collaborator
- EKOS Corporation
Record details
- Record id
cardio:ct-nct02396758- Content hash
97065ac93ca1f0afa9dc3e6b6830877e6192b117058004a55ba7c14071d31d7c